| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three months ended March 31, 2025 and 2024:
Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2024 |
|
| |
|
Three months ended March 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Preclinical, clinical trial and other costs |
|
$ |
1,197,035 |
|
|
$ |
1,031,280 |
|
| Research and development personnel expense(1) |
|
|
391,505 |
|
|
|
507,790 |
|
| Research and development
expense |
|
|
|
|
|
|
|
|
| General and administrative personnel expense(2) |
|
|
673,779 |
|
|
|
518,831 |
|
| General and administrative
expense |
|
|
|
|
|
|
|
|
| Administrative and facilities expense(3) |
|
|
584,671 |
|
|
|
751,697 |
|
| Other income, net |
|
|
(12,585 |
) |
|
|
(83,217 |
) |
| Total |
|
$ |
2,834,405 |
|
|
$ |
2,726,381 |
|
| (1) |
|
Research and development personnel costs include employee stock-based compensation expense of $46,720 and $31,121 for the three months
ended March 31, 2025 and 2024, respectively. |
| (2) |
|
General and administrative personnel costs include employee stock-based compensation expense of $122,655 and $38,871 for the three months
ended March 31, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC. |
| (3) |
|
Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting,
travel, and other administrative costs. |
|